NasdaqGS:NVAXBiotechs
Novavax (NVAX) Turns Profitable With US$440 Million TTM Net Income Challenging Bearish Views
Latest FY 2025 Results Set Up a Fresh Look at Novavax
Novavax (NVAX) has wrapped up FY 2025 with fourth quarter revenue of US$147.1 million and basic EPS of US$0.11, alongside trailing 12 month revenue of US$1.1 billion and EPS of US$2.72 that point to a very different earnings profile than a year ago. Over the past six quarters, the company has seen revenue move from US$88.3 million in Q4 2024 to US$666.7 million in Q1 2025, US$239.2 million in Q2, US$70.4 million in Q3, and now US$147.1...